NCT07035405

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX)

Colchicine for Secondary Prevention After Ischemic Stroke (CHANCE-3 EX): a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 7,500 (estimated)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The role of colchicine in the secondary prevention of ischemic stroke has not been determinded. This multicenter, randomized, double-blind, placebo-controlled, event-driven clinical trial of CHANCE-3 EX was aimed to assess the efficacy and safety of low-dose colchicine versus placebo on reducing the risk of recurrent ischemic stroke, myocardial infarction and vascular death in patients with minor-to-moderate ischemic stroke.

Conditions

• Stroke

Interventions

Type	Name	Description
DRUG	Colchicine 0.5 mg	Oral colchicine will be initiated with a dose of 0.5 mg per day.
DRUG	Placebo colchicine	Oral placebo colchicine will be initiated with a dose of 0.5 mg per day.

Timeline

• Start date: 2025-07-04
• Primary completion: 2028-12-31
• Completion: 2028-12-31
• First posted: 2025-06-25
• Last updated: 2025-06-27